Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zirconium Zr 89-DFO-YS5

Radiopharmaceutical · Acts on CD46 (membrane cofactor protein) (CD46)

Phase 1 Most advanced trial
1 Registered trials

What is Zirconium Zr 89-DFO-YS5?

Zirconium Zr 89-DFO-YS5 is a radioimmunoconjugate in which the YS5 human IgG1 antibody is linked via desferrioxamine to the radioisotope zirconium-89. The antibody binds a conformational epitope on CD46 in Sushi domains 1 and 2, enabling PET imaging of CD46-expressing tumor cells. It is studied in bladder cancer, nerve sheath tumors and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
[89Zr]DFO-YS5
Drug type
Radiopharmaceutical
Targets
CD46 (membrane cofactor protein) (CD46)
Mechanism
Acts on CD46 (membrane cofactor protein) (CD46)
Therapy area
Oncology
In trials of
KYNB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07664397 Phase 1 Bladder Cancer Recruiting KYNB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorBladder CancerBladder NeoplasmNerve Sheath NeoplasmsNerve Sheath TumorNerve Sheath Tumor, NosSolid CarcinomaSolid Tumor CancerSolid Tumor MalignanciesSolid Tumor NeoplasmsSolid Tumor, Adult

Other drugs acting on CD46

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.